1. Home
  2. IDE vs CRDF Comparison

IDE vs CRDF Comparison

Compare IDE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$12.28

Market Cap

177.6M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$2.80

Market Cap

142.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
CRDF
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.6M
142.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDE
CRDF
Price
$12.28
$2.80
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.83
AVG Volume (30 Days)
33.5K
1.1M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$501,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.61
$1.90
52 Week High
$10.46
$4.99

Technical Indicators

Market Signals
Indicator
IDE
CRDF
Relative Strength Index (RSI) 63.46 60.47
Support Level $12.05 $2.32
Resistance Level $12.10 $3.31
Average True Range (ATR) 0.10 0.17
MACD 0.03 0.03
Stochastic Oscillator 84.09 49.78

Price Performance

Historical Comparison
IDE
CRDF

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: